Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APYX Stock Forecast 2026-2027
$4.60
Current Price
$192.62M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to APYX Price Targets
+73.9%
To High Target of $8.00
+30.4%
To Median Target of $6.00
+30.4%
To Low Target of $6.00
APYX Price Momentum
-5.3%
1 Week Change
+13.6%
1 Month Change
+147.3%
1 Year Change
+31.4%
Year-to-Date Change
-9.4%
From 52W High of $5.08
+189.3%
From 52W Low of $1.59
📊 TOP ANALYST CALLS
Did APYX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Apyx Medical is one of their latest high-conviction picks.
Latest APYX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, APYX has a bullish consensus with a median price target of $6.00 (ranging from $6.00 to $8.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $4.60, the median forecast implies a 30.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Hewitt at Craig-Hallum, suggesting a 30.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APYX Analyst Ratings
4
Buy
0
Hold
0
Sell
APYX Price Target Range
Low
$6.00
Average
$6.00
High
$8.00
Current: $4.60
Latest APYX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APYX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | Craig-Hallum | Matthew Hewitt | Buy | Maintains | $6.00 |
| Mar 11, 2026 | BTIG | Sam Eiber | Buy | Upgrade | $6.00 |
| Dec 16, 2025 | Roth Capital | Buy | Initiates | $N/A | |
| Nov 12, 2025 | Citizens | Market Outperform | Upgrade | $N/A | |
| Oct 17, 2024 | BTIG | Neutral | Initiates | $N/A | |
| Sep 16, 2024 | JMP Securities | Market Perform | Reiterates | $N/A | |
| Nov 10, 2023 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Aug 11, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jul 14, 2023 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Jun 15, 2023 | Lake Street | Buy | Maintains | $N/A | |
| May 24, 2023 | JMP Securities | Market Perform | Reiterates | $N/A | |
| May 12, 2023 | Lake Street | Buy | Maintains | $N/A | |
| Dec 8, 2022 | Lake Street | Frank Takkinen | Buy | Assumes | $5.00 |
| Aug 12, 2022 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jul 19, 2022 | Lake Street | Buy | Maintains | $N/A | |
| May 20, 2022 | Lake Street | Buy | Initiates | $N/A | |
| Aug 13, 2021 | JMP Securities | Market Outperform | Maintains | $N/A | |
| May 12, 2020 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Nov 12, 2019 | Piper Jaffray | Overweight | Maintains | $N/A | |
| Nov 12, 2019 | Piper Sandler | Overweight | Maintains | $N/A |
Apyx Medical Corporation (APYX) Competitors
The following stocks are similar to Apyx Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Apyx Medical Corporation (APYX) Financial Data
Apyx Medical Corporation has a market capitalization of $192.62M with a P/E ratio of -17.0x. The company generates $55.90M in trailing twelve-month revenue with a -16.4% profit margin.
Revenue growth is +32.5% quarter-over-quarter, while maintaining an operating margin of -7.3% and return on equity of -76.5%.
Valuation Metrics
Market Cap
$192.62M
Enterprise Value
$204.97M
P/E Ratio
-17.0x
PEG Ratio
0.3x
Price/Sales
3.5x
Growth & Margins
Revenue Growth (YoY)
+32.5%
Gross Margin
+63.5%
Operating Margin
-7.3%
Net Margin
-16.4%
EPS Growth
+32.4%
Financial Health
Cash/Price Ratio
+16.2%
Current Ratio
5.8x
Debt/Equity
301.5x
ROE
-76.5%
ROA
-4.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Apyx Medical Corporation (APYX) Business Model
About Apyx Medical Corporation
What They Do
Advanced energy technology for electrosurgical equipment.
Business Model
The company generates revenue by designing, developing, and manufacturing electrosurgical equipment and medical devices. Its primary products include proprietary technologies marketed as Renuvion and J-Plasma for cosmetic and surgical applications, respectively. Additionally, Apyx Medical engages in OEM agreements to produce specialized devices for other manufacturers.
Additional Information
Apyx Medical is headquartered in Clearwater, Florida, and serves both domestic and international markets. The company focuses on enhancing surgical outcomes and patient care through innovative solutions, including the AYON Body Contouring System, which combines various modalities for effective body contouring.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
220
CEO
Mr. Charles D. Goodwin II
Country
United States
IPO Year
2019
Website
apyxmedical.comApyx Medical Corporation (APYX) Latest News & Analysis
Latest News
Quick Summary
Apyx Medical (NASDAQ:APYX) will showcase its Body by Apyx at Miami Swim Week, highlighting patient transformations using its Renuvion® and AYON Body Contouring System™.
Why It Matters
Apyx Medical's participation in Miami Swim Week highlights brand visibility and consumer engagement, potentially boosting sales and investor confidence in its surgical aesthetics products.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Recent data shows that a single-session treatment effectively reduces dimpling and promotes tissue remodeling.
Why It Matters
The news indicates potential advancements in cosmetic treatments, suggesting increased demand and revenue opportunities for companies in the aesthetic medicine market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apyx Medical Corporation (NASDAQ:APYX) announced the publication of a new retrospective study in Plastic and Reconstructive Surgery - Global Open, focusing on its Renuvion® and AYON systems.
Why It Matters
Apyx Medical's new study publication could enhance credibility and drive demand for its products, potentially boosting sales and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AYON is adding power liposuction as a second advanced modality, which is anticipated to enhance market demand for its liposuction offerings.
Why It Matters
The addition of power liposuction enhances AYON's product offerings, likely increasing demand and potentially boosting revenue and market share in the cosmetic surgery sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Apyx Medical Corporation (APYX) held its Q1 2026 earnings call, providing insights into financial performance and business developments. Further details can be found in the transcript.
Why It Matters
Apyx Medical's Q1 2026 earnings call provides insights into financial performance, growth prospects, and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Apyx Medical Corporation (NASDAQ: APYX) reported its Q1 financial results for 2026, focusing on its surgical aesthetics products, Renuvion® and AYON Body Contouring System™.
Why It Matters
Apyx Medical's Q1 financial results signal performance trends, impacting stock valuations and investor sentiment in the surgical aesthetics sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APYX Stock
What is Apyx Medical Corporation's (APYX) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Apyx Medical Corporation (APYX) has a median price target of $6.00. The highest price target is $8.00 and the lowest is $6.00.
Is APYX stock a good investment in 2026?
According to current analyst ratings, APYX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APYX stock?
Wall Street analysts predict APYX stock could reach $6.00 in the next 12 months. This represents a 30.4% increase from the current price of $4.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Apyx Medical Corporation's business model?
The company generates revenue by designing, developing, and manufacturing electrosurgical equipment and medical devices. Its primary products include proprietary technologies marketed as Renuvion and J-Plasma for cosmetic and surgical applications, respectively. Additionally, Apyx Medical engages in OEM agreements to produce specialized devices for other manufacturers.
What is the highest forecasted price for APYX Apyx Medical Corporation?
The highest price target for APYX is $8.00 from at , which represents a 73.9% increase from the current price of $4.60.
What is the lowest forecasted price for APYX Apyx Medical Corporation?
The lowest price target for APYX is $6.00 from Matthew Hewitt at Craig-Hallum, which represents a 30.4% increase from the current price of $4.60.
What is the overall APYX consensus from analysts for Apyx Medical Corporation?
The overall analyst consensus for APYX is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are APYX stock price projections?
Stock price projections, including those for Apyx Medical Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 10:32 AM UTC